Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls

Trial Profile

A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 6273340 (Primary) ; Ibuprofen; Pregabalin
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Nov 2017 Primary endpoint (Electrical pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
    • 27 Nov 2017 Primary endpoint (Pressure pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
    • 27 Nov 2017 Primary endpoint (Ultra-violet light sensitized pain detection threshold (50mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top